Induced pluripotent stem cell (iPSCs) are somatic cells reprogrammed into a pluripotent stem cell state by the expression of key transcriptional factors. Human iPSCs resemble many pluripotent properties of embryonic stem cells (ESCs), including the nearly unlimited self-renewal capacity and ability to differentiate into cells of all three germ layers. In contrast to ESCs, iPSCs can be derived from a patient's somatic cells, which overcomes concerns of immune rejection and the destruction of embryos. The iPSCs is thereby a promising patient-specific cell source for tissue engineering regenerative medicine.
This Research Topic is focusing on the state-of-the-art in biomaterials that advance iPSC-based tissue engineering technology for the creation of regenerative and therapeutic products. It will cover a wide spectrum of research subjects including (but will not be limited to):
- novel biomaterials for safe, efficient, and scalable iPSC reprogramming
- biomaterials and bioreactors designed for optimal in vitro iPSC expansion and differentiation
- ex vivo iPSC-derived disease model and high-throughput platform for epigenetic regulation
- functional tissue grafts consisting of biomaterials and differentiated iPSCs
- biomaterial strategies that drive iPSC-based pre-vascularization.
Photocredit: Andrew Agbay
Induced pluripotent stem cell (iPSCs) are somatic cells reprogrammed into a pluripotent stem cell state by the expression of key transcriptional factors. Human iPSCs resemble many pluripotent properties of embryonic stem cells (ESCs), including the nearly unlimited self-renewal capacity and ability to differentiate into cells of all three germ layers. In contrast to ESCs, iPSCs can be derived from a patient's somatic cells, which overcomes concerns of immune rejection and the destruction of embryos. The iPSCs is thereby a promising patient-specific cell source for tissue engineering regenerative medicine.
This Research Topic is focusing on the state-of-the-art in biomaterials that advance iPSC-based tissue engineering technology for the creation of regenerative and therapeutic products. It will cover a wide spectrum of research subjects including (but will not be limited to):
- novel biomaterials for safe, efficient, and scalable iPSC reprogramming
- biomaterials and bioreactors designed for optimal in vitro iPSC expansion and differentiation
- ex vivo iPSC-derived disease model and high-throughput platform for epigenetic regulation
- functional tissue grafts consisting of biomaterials and differentiated iPSCs
- biomaterial strategies that drive iPSC-based pre-vascularization.
Photocredit: Andrew Agbay
